SavedAdd your journal

Journals / The European Research Journal / 2026 / Volume: 11 Issue: 3

Interplay and clinicopathological correlates of tumor size, multifocality and aggressive variants in patients with operated differentiated thyroid carcinoma: A retrospective cohort study

Ercüment Gürlüler(Department of General Surgery, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye)0000-0002-6008-5494
Ali Vuslat Özen(Department of General Surgery, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye)0009-0001-8042-000X
Pages
—
Publication Date
2025-05-04
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Our findings revealed the presence of bilaterality/multifocality and aggressive variants in a considerable proportion of patients with operated DTC, and a multifaceted interplay between bilaterality/multifocality, tumor size, and PTC aggressive variants, in addition to their individual effects on increased risk of tumor invasion, particularly the extrathyroidal invasion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the interplay and clinicopathological correlates of tumor size, cancer foci (multifocality/bilaterality), and aggressive variants in patients with operated differentiated thyroid cancer (DTC).
📊
Key Findings & Data:Methods: A total of 596 patients with operated DTC (median age: 47.0 (range: 18.0-87.0 years, 77.5% were females) were included in this retrospective cohort study.
💡
Conclusion & Impact:Conclusions: Our findings revealed the presence of bilaterality/multifocality and aggressive variants in a considerable proportion of patients with operated DTC, and a multifaceted interplay between bilaterality/multifocality, tumor size, and PTC aggressive variants, in addition to their individual effects on increased risk of tumor invasion, particularly the extrathyroidal invasion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Differentiated thyroid cancer · cancer foci · tumor size

Abstract

Objectives: To investigate the interplay and clinicopathological correlates of tumor size, cancer foci (multifocality/bilaterality), and aggressive variants in patients with operated differentiated thyroid cancer (DTC). Methods: A total of 596 patients with operated DTC (median age: 47.0 (range: 18.0-87.0 years, 77.5% were females) were included in this retrospective cohort study. Data on patient demographics, cancer foci, concomitant Hashimoto's thyroiditis, surgery type, DTC subtype (papillary thyroid cancer [PTC], follicular thyroid cancer [FTC]) and variants, tumor size, lymph node metastasis, tumor invasion were recorded. Results: PTC aggressive variant (21.9%, P=0.045), extrathyroidal invasion (24.6%, P=0.012), tall cell PTC variant (60.3%, P=0.043), and widely invasive FTC variants (60.0% P=0.002) rates were significantly higher in the bilateral multifocal tumors than in the unifocal and unilateral multifocal tumors. The rates of Hashimoto's thyroiditis (59.8%, P<0.001) and PTC subtype (99.6%, P<0.001) were significantly higher, while the rates of lymph node metastasis (5.8%, P<0.001), capsule invasion (11.6%, P<0.001), vascular invasion (0.4%, P<0.001) and extrathyroidal invasion (4.5%, P<0.001) were significantly lower in <10 mm than in >10 mm tumors. Presence vs. absence of PTC aggressive variant was associated with significantly higher greatest tumor size (12 mm, P=0.013) and higher rates of multifocal tumor (50.5%, P=0.013) and extrathyroidal invasion (33.0%, P<0.001). Conclusions: Our findings revealed the presence of bilaterality/multifocality and aggressive variants in a considerable proportion of patients with operated DTC, and a multifaceted interplay between bilaterality/multifocality, tumor size, and PTC aggressive variants, in addition to their individual effects on increased risk of tumor invasion, particularly the extrathyroidal invasion.

🔖

Cite This Article

Gürlüler, E., Özen, A. V. (2025). Interplay and clinicopathological correlates of tumor size, multifocality and aggressive variants in patients with operated differentiated thyroid carcinoma: A retrospective cohort study. The European Research Journal, Volume: 11 Issue: 3. https://doi.org/10.18621/eurj.1598676

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (30)

  1. Megwalu U, Moon P. Thyroid cancer incidence and mortality trends in the United States: 2000–2018. Thyroid. 2022;32(5):560-570. doi: 10.1089/thy.2021.0662.
  2. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31-40. doi: 10.1002/cncr.11442.
  3. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S150-S160. doi: 10.1017/S0022215116000578.
  4. Póvoa AA, Teixeira E, Bella-Cueto MR, et al. Clinicopathological features as prognostic predictors of poor outcome in papillary thyroid carcinoma. Cancers. 2020;12(11):3186. doi: 10.3390/cancers12113186.
  5. Zhang T, He L, Wang Z, et al. The Differences Between Multifocal and Unifocal Papillary Thyroid Carcinoma in Unilateral Lobe: A Meta-Analysis. Front Oncol. 2021;11:657237. doi: 10.3389/fonc.2021.657237.
  6. Sapuppo G, Grasso S, Di Benedetto G, et al. Is multifocality a risk factor in low-risk papillary thyroid cancer? Endokrynol Pol. 2022;73(6):928-934. doi: 10.5603/EP.a2022.0073.
  7. Muzza M. The clonal origin of multifocal papillary thyroid cancer: intrathyroidal spread or independent tumors? Minerva Endocrinol (Torino). 2021;46(1):35-44. doi: 10.23736/S2724-6507.20.03302-7.
  8. Kim Y, An S, Park J, Bae JS, Kim JS, Kim K. Clinical Implication of Bilateral and Unilateral Multifocality in Papillary Thyroid Carcinoma: A Propensity Score-Matched Study. Cancers (Basel). 2023;15(14):3596. doi: 10.3390/cancers15143596.
  9. Huang G, Tian X, Li Y, Ji F. Clinical characteristics and surgical resection of multifocal papillary thyroid carcinoma: 168 cases. Int J Clin Exp Med. 2014;7(12):5802-5807.
  10. Gur EO, Karaisli S, Haciyanli S, et al. Multifocality related factors in papillary thyroid carcinoma. Asian J Surg. 2019;42(1):297-302. doi: 10.1016/j.asjsur.2018.05.004.
  11. Parvathareddy SK, Siraj AK, Annaiyappanaidu P, et al. Bilateral multifocality is an independent predictor of patients' outcome in Middle Eastern papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2023;13:1060301. doi: 10.3389/fendo.2022.1060301.
  12. Kiriakopoulos A, Petralias A, Linos D. Multifocal versus solitary papillary thyroid carcinoma. World J Surg. 2016;40(9):2139-2143. doi: 10.1007/s00268-016-3628-5.
  13. Joseph KR, Edirimanne S, Eslick GD. Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg. 2018;50:121-125. doi: 10.1016/j.ijsu.2017.12.035.
  14. Vuong HG, Duong UNP, Pham TQ, et al. Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis. World J Surg. 2018;42(4):1005-1017. doi: 10.1007/s00268-017-4206-1.
  15. Wang P, Wang Y, Miao C, et al. Defining a new tumor dimension in staging of papillary thyroid carcinoma. Ann Surg Oncol. 2017;24(6):1551-1556. doi: 10.1245/s10434-017-5764-z.
  16. Miccoli P, Minuto MN, Ugolini C, et al. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. World J Surg. 2007;31(5):888-894. doi: 10.1007/s00268-006-0795-9.
  17. Kim KJ, Kim SM, Lee YS, Chung WY, Chang HS, Park CS. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol. 2015;22(1):125-131. doi: 10.1245/s10434-014-3899-8.
  18. Glikson E, Alon E, Bedrin L, Talmi YP. Prognostic Factors in Differentiated Thyroid Cancer Revisited. Isr Med Assoc J. 2017;19(2):114-118.
  19. Yihao L, Shuo L, Pu X, et al. Risk Factors for Contralateral Occult Papillary Thyroid Carcinoma in Patients with Clinical Unilateral Papillary Thyroid Carcinoma: A Case-Control Study. Int J Endocrinol. 2022;2022:5112985. doi: 10.1155/2022/5112985.
  20. Iacobone M, Jansson S, Barczyński M, Goretzki P. Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):141-154. doi: 10.1007/s00423-013-1145-7.
  21. Park KW, Han AY, Kim CM, Wang MB, Nguyen CT. Is lobectomy sufficient for multifocal papillary thyroid microcarcinoma? Am J Otolaryngol. 2023;44(4):103881. doi: 10.1016/j.amjoto.2023.103881.
  22. Lloyd RV, Osamura RY, Klöppel G, Rosai J, eds. WHO Classification of Tumours of Endocrine Organs. WHO Classification of Tumours. 4th ed. Volume 10. Lyon: IARC; 2017.
  23. Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: Current evidence on clinicopathologic features and molecular biology. Oncotarget. 2016;7(26):40792-40799. doi: 10.18632/oncotarget.8215.
  24. Khan U, Al Afif A, Aldaihani A, et al. Patient and tumor factors contributing to distant metastasis in well-differentiated thyroid cancer: a retrospective cohort study. J Otolaryngol Head Neck Surg. 2020;49(1):78. doi: 10.1186/s40463-020-00469-8.
  25. Hirokawa M, Maekawa M, Kuma S, Miyauchi A. Cribriform-morular variant of papillary thyroid carcinoma--cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol. 2010;38(12):890-896. doi: 10.1002/dc.21309.
  26. Ito Y, Miyauchi A, Ishikawa H, et al. Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J. 2011;58(8):685-689. doi: 10.1507/endocrj.ej11-0022.
  27. Park SY, Jung YS, Ryu CH, et al. Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma. Endocr Relat Cancer. 2015;22(4):679-686. doi: 10.1530/ERC-15-0152.
  28. Koo BS, Lim HS, Lim YC, et al. Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17(4):1101-1105. doi: 10.1245/s10434-009-0906-6.
  29. Miyauchi A. Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. World J Surg. 2016;40(3):516-522. doi: 10.1007/s00268-015-3392-y.
  30. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111(6):508-516. doi: 10.1002/cncr.23116.